<div class="table-wrap">
<div id="ehy310-T3" data-id="ehy310-T3" class="table-wrap-title">
<div class="label -label">Table 3</div>
<div class="caption"><p>Incidence
 rates (per 100 person years) and hazard ratios for cardiovascular 
endpoints and total mortality in CANTOS, according to on-treatment 
tertiles of interleukin-6 achieved at 3 months among those allocated to 
canakinumab</p></div> </div>
<div class="table-overflow"><table>
<thead name="thead" align=""><tr>
<th>Treatment group, on-treatment IL-6 threshold </th>
<th>
<em>N</em> </th>
<th>Incidence rate (<em>n</em>)<a reveal-id="tblfn5" data-open="tblfn5" class="link link-ref link-reveal xref-fn"><sup>a</sup></a> </th>
<th>HR (95% CI) </th>
<th>
<em>P</em>-value </th>
<th>HR<a reveal-id="tblfn5" data-open="tblfn5" class="link link-ref link-reveal xref-fn"><sup>a</sup></a><sup>djusted</sup> (95% CI)<a reveal-id="tblfn6" data-open="tblfn6" class="link link-ref link-reveal xref-fn"><sup>b</sup></a> </th>
<th>
<em>P</em>-value </th>
</tr></thead>
<tbody>
<tr>
<td>MACE </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>4.91 (282) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 top tertile<a reveal-id="tblfn7" data-open="tblfn7" class="link link-ref link-reveal xref-fn"><sup>c</sup></a> </td>
<td>1098 </td>
<td>5.66 (213) </td>
<td>1.17 (0.98–1.39) </td>
<td>0.092 </td>
<td>0.99 (0.82–1.19) </td>
<td>0.89 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 middle tertile </td>
<td>1059 </td>
<td>3.88 (150) </td>
<td>0.79 (0.65–0.96) </td>
<td>0.0203 </td>
<td>0.73 (0.60–0.90) </td>
<td>0.0029 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 lowest tertile </td>
<td>1079 </td>
<td>3.01 (127) </td>
<td>0.60 (0.49–0.74) </td>
<td>&lt;0.0001 </td>
<td>0.65 (0.53–0.81) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>MACE+ </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>5.49 (311) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 top tertile<a reveal-id="tblfn7" data-open="tblfn7" class="link link-ref link-reveal xref-fn"><sup>c</sup></a> </td>
<td>1098 </td>
<td>6.00 (224) </td>
<td>1.10 (0.93–1.31) </td>
<td>0.27 </td>
<td>0.96 (0.80–1.14) </td>
<td>0.62 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 middle tertile </td>
<td>1059 </td>
<td>4.26 (163) </td>
<td>0.78 (0.64–0.94) </td>
<td>0.0090 </td>
<td>0.72 (0.60–0.88) </td>
<td>0.0012 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 lowest tertile </td>
<td>1079 </td>
<td>3.50 (146) </td>
<td>0.63 (0.51–0.76) </td>
<td>&lt;0.0001 </td>
<td>0.68 (0.56–0.83) </td>
<td>0.0002 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>Cardiovascular mortality </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>1.66 (103) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 top tertile<a reveal-id="tblfn7" data-open="tblfn7" class="link link-ref link-reveal xref-fn"><sup>c</sup></a> </td>
<td>1098 </td>
<td>2.54 (102) </td>
<td>1.55 (1.18–2.04) </td>
<td>0.0016 </td>
<td>1.27 (0.96–1.70) </td>
<td>0.10 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 middle tertile </td>
<td>1059 </td>
<td>1.34 (55) </td>
<td>0.81 (0.58–1.13) </td>
<td>0.21 </td>
<td>0.76 (0.54–1.06) </td>
<td>0.11 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 lowest tertile </td>
<td>1079 </td>
<td>0.58 (26) </td>
<td>0.35 (0.23–0.53) </td>
<td>&lt;0.0001 </td>
<td>0.41 (0.27–0.64) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>Total mortality </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>2.86 (177) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 top tertile<a reveal-id="tblfn7" data-open="tblfn7" class="link link-ref link-reveal xref-fn"><sup>c</sup></a> </td>
<td>1098 </td>
<td>4.50 (181) </td>
<td>1.61 (1.31–1.98) </td>
<td>&lt;0.0001 </td>
<td>1.33 (1.07–1.65) </td>
<td>0.0108 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 middle tertile </td>
<td>1059 </td>
<td>2.22 (91) </td>
<td>0.78 (0.60–1.00) </td>
<td>0.0486 </td>
<td>0.74 (0.57–0.96) </td>
<td>0.0210 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 lowest tertile </td>
<td>1079 </td>
<td>1.12 (50) </td>
<td>0.39 (0.29–0.53) </td>
<td>&lt;0.0001 </td>
<td>0.47 (0.34–0.65) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
</tbody>
</table></div>
<div content-id="ehy310-T3" class="table-modal"><table>
<thead name="thead" align=""><tr>
<th>Treatment group, on-treatment IL-6 threshold </th>
<th>
<em>N</em> </th>
<th>Incidence rate (<em>n</em>)<a reveal-id="tblfn5" data-open="tblfn5" class="link link-ref link-reveal xref-fn"><sup>a</sup></a> </th>
<th>HR (95% CI) </th>
<th>
<em>P</em>-value </th>
<th>HR<a reveal-id="tblfn5" data-open="tblfn5" class="link link-ref link-reveal xref-fn"><sup>a</sup></a><sup>djusted</sup> (95% CI)<a reveal-id="tblfn6" data-open="tblfn6" class="link link-ref link-reveal xref-fn"><sup>b</sup></a> </th>
<th>
<em>P</em>-value </th>
</tr></thead>
<tbody>
<tr>
<td>MACE </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>4.91 (282) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 top tertile<a reveal-id="tblfn7" data-open="tblfn7" class="link link-ref link-reveal xref-fn"><sup>c</sup></a> </td>
<td>1098 </td>
<td>5.66 (213) </td>
<td>1.17 (0.98–1.39) </td>
<td>0.092 </td>
<td>0.99 (0.82–1.19) </td>
<td>0.89 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 middle tertile </td>
<td>1059 </td>
<td>3.88 (150) </td>
<td>0.79 (0.65–0.96) </td>
<td>0.0203 </td>
<td>0.73 (0.60–0.90) </td>
<td>0.0029 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 lowest tertile </td>
<td>1079 </td>
<td>3.01 (127) </td>
<td>0.60 (0.49–0.74) </td>
<td>&lt;0.0001 </td>
<td>0.65 (0.53–0.81) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>MACE+ </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>5.49 (311) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 top tertile<a reveal-id="tblfn7" data-open="tblfn7" class="link link-ref link-reveal xref-fn"><sup>c</sup></a> </td>
<td>1098 </td>
<td>6.00 (224) </td>
<td>1.10 (0.93–1.31) </td>
<td>0.27 </td>
<td>0.96 (0.80–1.14) </td>
<td>0.62 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 middle tertile </td>
<td>1059 </td>
<td>4.26 (163) </td>
<td>0.78 (0.64–0.94) </td>
<td>0.0090 </td>
<td>0.72 (0.60–0.88) </td>
<td>0.0012 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 lowest tertile </td>
<td>1079 </td>
<td>3.50 (146) </td>
<td>0.63 (0.51–0.76) </td>
<td>&lt;0.0001 </td>
<td>0.68 (0.56–0.83) </td>
<td>0.0002 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>Cardiovascular mortality </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>1.66 (103) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 top tertile<a reveal-id="tblfn7" data-open="tblfn7" class="link link-ref link-reveal xref-fn"><sup>c</sup></a> </td>
<td>1098 </td>
<td>2.54 (102) </td>
<td>1.55 (1.18–2.04) </td>
<td>0.0016 </td>
<td>1.27 (0.96–1.70) </td>
<td>0.10 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 middle tertile </td>
<td>1059 </td>
<td>1.34 (55) </td>
<td>0.81 (0.58–1.13) </td>
<td>0.21 </td>
<td>0.76 (0.54–1.06) </td>
<td>0.11 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 lowest tertile </td>
<td>1079 </td>
<td>0.58 (26) </td>
<td>0.35 (0.23–0.53) </td>
<td>&lt;0.0001 </td>
<td>0.41 (0.27–0.64) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>Total mortality </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>2.86 (177) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 top tertile<a reveal-id="tblfn7" data-open="tblfn7" class="link link-ref link-reveal xref-fn"><sup>c</sup></a> </td>
<td>1098 </td>
<td>4.50 (181) </td>
<td>1.61 (1.31–1.98) </td>
<td>&lt;0.0001 </td>
<td>1.33 (1.07–1.65) </td>
<td>0.0108 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 middle tertile </td>
<td>1059 </td>
<td>2.22 (91) </td>
<td>0.78 (0.60–1.00) </td>
<td>0.0486 </td>
<td>0.74 (0.57–0.96) </td>
<td>0.0210 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 lowest tertile </td>
<td>1079 </td>
<td>1.12 (50) </td>
<td>0.39 (0.29–0.53) </td>
<td>&lt;0.0001 </td>
<td>0.47 (0.34–0.65) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
</tbody>
</table></div>
<div class="table-wrap-foot">
<div content-id="tblfn5"><div class="fn">
<div class="label -label">a</div>
<p>Per 100 person-years of exposure.</p>
</div></div>
<div content-id="tblfn6"><div class="fn">
<div class="label -label">b</div>
<p>Covariates
 included in the adjusted multivariable model include age, gender, 
smoking status, hypertension, diabetes, body mass index, baseline level 
of IL-6, and baseline level of LDL cholesterol.</p>
</div></div>
<div content-id="tblfn7"><div class="fn">
<div class="label -label">c</div>
<p>Tertile cutpoints for on-treatment IL-6 levels at 3 months were &gt;2.22 mg/L, &gt;1.25–2.22 mg/L, and ≤1.25 ng/L.</p>
</div></div>
<div content-id="tblfn8"><div class="fn"><p>The median percent reduction in IL-6 at 3-months was −34.9.</p></div></div>
</div>
</div>